FDA
-
-
-
-
-
-
-
Ironwood Pharmaceuticals (IRWD) PT Raised to $5 at Wells Fargo
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
-
-
-
-
-
-
-
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Reports Publication of New Linaclotide Phase III Data
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Announces FDA Approval of New Indication for LINZESS for Functional Constipation in Pediatric Patients Ages 6-17 Years-Old
-
322,963 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

